Subtype
Virus-Related Malignant Neoplasm
CI-CAN-00001652Explore in graph →
132 active trials4 approved drugs1 evidence items
- NCIt
- C27673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001652Explore in graph →
Clinical trials
537 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 |
| clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma | terminated | Phase 2 | 1 | Amit VermaOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | terminated | Phase 1 / Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01495598 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01775475 | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | completed | Phase 2 | 7 | AIDS Malignancy ConsortiumNETWORK | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT00858793 | High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT | terminated | Phase 1 / Phase 2 | 5 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04065152 | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma(KAPVEC) | unknown | Phase 2 | 20 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04436133 | Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | completed | Phase 2 | 480 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03296553 | Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. | completed | Phase 2 | 40 | National Institute of CancerologíaOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT00001563 | EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2022 | clinicaltrials |
| NCT00000996 | A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 2 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000687 | Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 2 | 60 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00001114 | The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma | completed | Phase 2 | 90 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 2 | Nov 1, 2021 | clinicaltrials |
| NCT00000807 | Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy | completed | Phase 2 | 41 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01276236 | Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) | completed | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02670616 | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00082888 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 16, 2024source: clinicaltrials